CUB domain-containing protein 1 (CDCP1)

CUB domain-containing protein 1 (CDCP1) is a type I transmembrane glycoprotein of approximately 135–140 kDa, predominantly found at the plasma membrane and highly expressed in many epithelial tumors[1][3][5][6]. The protein contains three extracellular CUB domains that facilitate cell-cell and cell-matrix interactions and a cytoplasmic region with multiple tyrosine phosphorylation sites essential for signal transduction[1][3][4][5][7][9]. Proteolytic cleavage of CDCP1 modulates its activity and the release of specific fragments is associated with tumor progression[1][7]. CDCP1 acts as a substrate and scaffold for Src family kinases, mediating downstream effects such as migration, adhesion, anoikis resistance, matrix degradation, and metastasis. Overexpression and activation of CDCP1 are linked to poor prognosis in multiple cancers, including breast, colon, lung, bladder, and pancreatic carcinomas[1][2][5][6]. Recent preclinical and translational research identifies CDCP1 as both a biomarker and a promising therapeutic target, with antibody-drug conjugates and radiolabeled antibodies in development for tumor detection and treatment[2][6].

Other names

CD318TraskSIMA135gp140

Antibody-drug conjugates induce targeted cancer cell death; Radiolabeled antibodies mediate targeted radiotherapy; SFK (Src family kinase) inhibition via small molecules blocks downstream signaling